You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

Details for Patent: 11,142,528

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 11,142,528 protect, and when does it expire?

Patent 11,142,528 protects BRUKINSA and is included in one NDA.

This patent has thirty-two patent family members in twenty-six countries.

Summary for Patent: 11,142,528

Patent landscape, scope, and claims:

Title:	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators
Abstract:	The invention is fused heterocyclic compounds of formula (I), and salts thereof, compositions thereof, and methods of use therefor. In particular, disclosed herein are certain fused heterocyclic compounds that can be useful for inhibiting protein kinase, including Bruton's tyrosine kinase (Btk), and for treating disorders mediated thereby. ##STR00001##
Inventor(s):	Wang; Zhiwei (Beijing, CN), Guo; Yunhang (Beijing, CN)
Assignee:	BEIGENE SWITZERLAND GMBH (Basel, CH)
Application Number:	16/739,447
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 11,142,528

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	11,142,528	⤷ Subscribe	Y			TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	⤷ Subscribe
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	11,142,528	⤷ Subscribe	Y			TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)	⤷ Subscribe
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	11,142,528	⤷ Subscribe	Y			FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA	⤷ Subscribe
Beigene	BRUKINSA	zanubrutinib	CAPSULE;ORAL	213217-001	Nov 14, 2019		RX	Yes	Yes	11,142,528	⤷ Subscribe	Y			TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 11,142,528

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
China	PCT/CN2013/074728	Apr 25, 2013

International Family Members for US Patent 11,142,528

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2989106	⤷ Subscribe	301161	Netherlands	⤷ Subscribe
European Patent Office	2989106	⤷ Subscribe	PA2022504	Lithuania	⤷ Subscribe
European Patent Office	2989106	⤷ Subscribe	LUC00250	Luxembourg	⤷ Subscribe
European Patent Office	2989106	⤷ Subscribe	CA 2022 00008	Denmark	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.